debt_leverage_profile
Minimal debt; Xencor holds ~$800M+ cash/investments with negligible long-term debt, making 20bps rate shift immaterial to leverage
Inferred
Agent_Inference
interest_rate_sensitivity
Low sensitivity; company is net cash-positive, so rising rates modestly boost interest income rather than increase financing costs
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Contract manufacturing biologics (CMOs like Lonza); API ingredients sourced from limited global suppliers; China/EU CMO concentration is key chokepoint
Inferred
Agent_Inference
international_expansion_readiness
Minimal direct international revenue; collaboration royalties primarily USD-denominated, limiting sovereign currency devaluation exposure materially
Inferred
Agent_Inference
geographic_footprint
Primarily US-based revenue; international exposure via Janssen/MorphoSys partnerships is largely USD-contractual, limiting FX devaluation risk
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High dependency on select CMOs (e.g., Lonza) for clinical-stage biologics manufacturing; switching costs are high and timelines long
Inferred
Agent_Inference
business_model_type_primary
Biopharmaceutical IP licensing and drug development; not cloud-dependent for revenue generation; cloud termination would disrupt R&D IT, not commercial ops
Inferred
Agent_Inference
business_model_type_secondary
Collaboration/milestone model with pharma partners (Janssen, Alexion); cloud disruption would cause operational delay but not immediate revenue loss
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; uses internal XmAb platform, not third-party software APIs; proprietary biologic platform creates scientific rather than software lock-in
Inferred
Agent_Inference
howey_test_risk_index
Not applicable; revenue from pharma collaborations, milestones, and royalties is clearly product/IP licensing, not an investment contract under Howey
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate; handles patient clinical trial data subject to GDPR (EU trials) and HIPAA; CCPA exposure limited as no direct consumer data collection
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; niche bispecific antibody platform with no dominant market share; collaborative model with large pharma reduces monopoly concerns
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~70-80% transactional/milestone-based; royalty streams from Monjuvi/tafasitamab provide modest recurring revenue; highly lumpy milestone recognition
Inferred
Agent_Inference
monetization_vector
Upfront collaboration fees, development milestones, regulatory milestones, and tiered royalties on partner commercialized products
Inferred
Agent_Inference
pricing_architecture
Milestone and royalty rates set contractually at deal signing; limited ability to renegotiate mid-contract; pricing stress occurs if partner pipeline fails
Inferred
Agent_Inference
pricing_power_rating
Moderate; XmAb platform differentiation supports premium deal terms, but large pharma partners have negotiating leverage on royalty rates
Inferred
Agent_Inference
target_gross_margin_bracket
85-95% gross margin on collaboration/royalty revenue; R&D expenses are operating costs, not COGS; typical biotech IP licensing margin profile
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider problem; proprietary XmAb technology is patented and licensed exclusively; no open-source or public-good leakage risk
Inferred
Agent_Inference
headcount_cost_structure
Sublinear growth possible; platform-based model means new drug candidates leverage existing XmAb IP without proportional headcount increases
Inferred
Agent_Inference
marginal_cost_of_growth
Low marginal cost per new collaboration; incremental pipeline assets use existing platform; CMO manufacturing costs borne largely by partners post-licensing
Inferred
Agent_Inference
franchise_compliance_risk
null
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, partnership deal flow would require larger BD/legal teams but R&D platform scales efficiently; unit economics improve with royalty compounding
Inferred
Agent_Inference
network_effect_present
No traditional network effects; scientific reputation and platform validation create weak positive feedback loop attracting better partners over time
Inferred
Agent_Inference
asset_efficiency_ratio
-10.2% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate resilience; pharma partnership revenue partially insulated from consumer cycles, but milestone payments depend on partner R&D budget prioritization
Inferred
Agent_Inference
customer_segment_primary
Large biopharmaceutical companies (Janssen, Alexion/AstraZeneca, MorphoSys/Incyte) licensing XmAb antibody engineering platform
Inferred
Agent_Inference
customer_segment_secondary
Mid-size biotechs seeking engineered antibody technologies; secondary revenue from Monjuvi royalties via Incyte commercial partnership
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
2.5% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001326732
High
SEC-EDGAR
ticker
XNCR
High
SEC-EDGAR